4 Stocks to Watch This Week

There's never a dull week on Wall Street. Let's go over some of the news that will shape the week to come.

Monday
Peregrine Pharmaceuticals  (NASDAQ: PPHM  )  kicks off the new trading week with its latest quarterly report on Monday afternoon. Peregrine is researching monoclonal antibodies for the treatment and diagnosis of cancer.

No one's holding out for a profit. Peregrine is still at least a couple of years away from profitability and meaningful revenue. However, every quarterly conference call affords Peregrine the chance to update investors on its progress. 

Wednesday
Bank of America  (NYSE: BAC  )  becomes the third of the "too big to fail" banks to report this earnings season when it steps up with updated financials on Wednesday. The first bank to report, Wells Fargo, posted a sharp drop in mortgage revenue on Friday, so naturally investors will be keeping an eye on how Bank of America is holding up on that front.  

Thursday
Advanced Micro Devices  (NYSE: AMD  )  checks in with its quarterly results on Thursday. AMD has done an admirable job of moving beyond its microprocessor business for PCs with its chips now powering all three of the world's largest video game consoles. The new strategy's been paying off for AMD. After a brief run in the red, AMD has come through with three consecutive profitable quarters. It hopes to stretch that streak to four quarters on Thursday afternoon.

Friday
The last day of the trading week is typically a quiet one, but that certainly isn't the case when earnings season rolls around. Several notable companies will be updating the market on their fiscal performances, but the biggest name here will be General Electric (NYSE: GE  ) in the morning. Analysts see revenue and earnings per share climbing 3% and 8%, respectively.

Trend Tracker: Warren Buffett: This new technology is a "real threat"
At the recent Berkshire Hathaway annual meeting, Warren Buffett admitted that an emerging technology is threatening the Oracle of Omaha's bread and butter. And it's no long a question of if, but when, according to the industry's foremost research firm. Find out how you can cash in on this technology before the crowd catches on, by jumping on to one company that could get you the biggest piece of the action. All the details are laid out in a new free investor alert from The Motley Fool. Click here now to learn more!

Editor's note: A previous version of this article incorrectly suggested an impending regulatory catalyst for MannKind. The passage has been removed. The Motley Fool regrets the error.


Read/Post Comments (6) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 12, 2014, at 2:05 PM, BiotekResearch wrote:

    Rick Munarriz, you seem like a very astute lead analyst for Motley Fool. I too hope that the diabetic community receives a new option for treatment. In fact, I'm willing to bet you $62714 and a case of Dos Equis that Afrezza gets FDA approval.

  • Report this Comment On July 12, 2014, at 2:47 PM, markloftus wrote:

    the afrezza drug already got approved you nim-wit

  • Report this Comment On July 12, 2014, at 2:47 PM, BrainDamage223 wrote:

    Rick, it's a good thing you don't actually own any shares on MNKD, given the (lack of) attention you've been paying to major events relating to the company...LOL

  • Report this Comment On July 12, 2014, at 3:10 PM, Phaeton wrote:

    Rick are you Rip Van Winkle? Perhaps we will see the impact of your article when the market opens on Monday and MNKD goes up on the exciting news of the potential of FDA approval on Tuesday 7/15. If it goes up from $10.05 to $15.00 on your news of making the 5 stocks to watch list for next week then I owe you a dinner. I know that your influence in the market is only 2nd to Jim Cramer. Do you have any prediction after MNKD FDA approval as to potential partnership or Buy out? Perhaps that will come after FDA approval. Assuming they get FDA approval. Wake up Rip Van Winkle.

  • Report this Comment On July 12, 2014, at 6:40 PM, antim98 wrote:

    Rick,

    You should be embarrased about your lack of attention regarding mankind and the approval that has already occured. At the very least, your faiure to double check your facts shows you pay little attention. At the worst, it makes readers think twice about trusting your judgement.

  • Report this Comment On July 14, 2014, at 3:40 PM, wildpig wrote:

    what judgement?

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3026687, ~/Articles/ArticleHandler.aspx, 11/26/2014 11:36:18 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement